8-K: Humana Reports Q4 2024 Loss, Reaffirms FY 2025 EPS Guidance Amid Membership Decline

Humana reports a net loss for Q4 2024 but reaffirms its FY 2025 EPS guidance, anticipating a significant decline in Medicare Advantage membership.

Summary

• Humana reported a net loss per share of $5.76 on a GAAP basis and an adjusted net loss per share of $2.16 for the fourth quarter of 2024.
• For the full year 2024, Humana reported earnings per share of $9.98 on a GAAP basis and $16.21 on an adjusted basis.
• The Insurance segment's adjusted benefit ratio for Q4 2024 was 91.9 percent, including a 20-basis point increase related to Star Ratings investments.
• Humana reaffirms its adjusted FY 2025 EPS guidance to be 'at least in line with 2024 results,' projecting approximately $15.88 GAAP EPS or $16.25 on an adjusted basis.
• The company expects an individual Medicare Advantage annual membership decline of approximately 550,000, or about 10 percent, from 2024.
• Humana is continuing to advance its Medicaid and CenterWell strategies, expecting them to drive increased earnings contribution over the mid and longer term.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While Humana reaffirms its EPS guidance, the reported loss and expected membership decline raise concerns. The company's strategic initiatives and long-term outlook provide some optimism, but the near-term challenges are significant.

Positives

• Humana's adjusted EPS for 2024 was in line with guidance at $16.21.
• The company reaffirmed its 2025 outlook to be at least in line with 2024 results.
• Humana grew individual Medicare Advantage membership by over 250,000, or approximately 5%, in 2024.
• The company is expanding its Medicaid footprint, now spanning 13 states.
• CenterWell Primary Care is expected to see solid growth through center additions and expansion of the IPA model.
• Humana Military successfully transitioned to the new T-5 contract.

Negatives

• Humana reported a net loss per share for Q4 2024.
• The company expects a significant decline in individual Medicare Advantage membership of approximately 550,000 in 2025.
• There is uncertainty in the pace of Stars recovery, posing a risk to achieving a 3% individual MA pretax margin by 2027.
• The company anticipates margin pressure in Group MA in 2025 due to pricing cycles.
• Investment income is expected to decrease in 2025 due to rate cuts.

Risks

• Uncertainty in the pace of Stars recovery may impact the ability to achieve a 3% individual MA pretax margin by 2027.
• Changes in special election period (SEP) rules for D-SNP members in 2025 create uncertainty in membership activity.
• The company faces potential challenges in ensuring rates in newly implemented Medicaid states are updated to reflect recent trend experience.
• There is a risk that the Texas and Georgia Medicaid awards may not move forward in 2026 due to ongoing protests.
• The company acknowledges risk regarding overall 2026 Star results given the limited timeframe to impact results post receipt of the 2025 Star results.

Future Outlook

Humana expects adjusted EPS of approximately $16.25 for 2025, with consolidated revenue between $126 billion and $128 billion. The company anticipates a decline in individual Medicare Advantage membership but growth in Medicaid and PDP membership.

Management Comments

• We were pleased with Humana's solid finish to the year, while also reaffirming our outlook for 2025, said Jim Rechtin, Humana's President and Chief Executive Officer.
• We are confident in our long-term strategy and 2025 will be a critical step in returning to compelling, normalized margins.

Industry Context

Humana's results and outlook reflect the ongoing challenges and opportunities in the managed care industry, including reimbursement pressures, regulatory changes (IRA), and the increasing importance of value-based care. The company's focus on expanding its CenterWell and Medicaid businesses aligns with the broader industry trend of diversification and integration of healthcare services.

Comparison to Industry Standards

• Humana's individual Medicare Advantage membership decline contrasts with some competitors who are experiencing growth, indicating potential market share shifts.
• The company's focus on value-based care models aligns with industry trends, but the success of these initiatives will depend on Humana's ability to effectively manage costs and improve outcomes.
• Humana's Medicaid expansion mirrors other large insurers seeking growth in government-sponsored healthcare programs, but profitability in this segment can be highly variable and dependent on state-specific factors.
• The company's Star Ratings challenges are a significant concern, as these ratings directly impact reimbursement rates and competitive positioning; recovery in this area is critical for future success.

Stakeholder Impact

• Shareholders will be impacted by the reported loss and potential stock price volatility.
• Members may experience changes in plan offerings due to the company's decision to exit certain unprofitable plans and counties.
• Employees may be affected by ongoing value creation initiatives and efforts to drive productivity and efficiency.
• Providers may see changes in contracting and reimbursement models as Humana expands its value-based care arrangements.

Next Steps

• Humana will host a live question and answer session for analysts to discuss the financial results and future expectations.
• The company will continue to implement initiatives to improve Star Ratings performance.
• Humana will monitor PDP performance and adjust expectations as appropriate based on performance.
• The company will re-evaluate its capital deployment plans throughout the year.
• Humana will focus on scaling its Primary Care portfolio in key geographies.

Key Dates

Keywords

Medicare Advantage, Medicaid, CenterWell, EPS, Star Ratings, Membership, Benefit Ratio, Humana, Financial Results